Hansa Biopharma AB's total assets for Q3 2025 were kr741.11M, a decrease of -11.49% from the previous quarter. SE:HNSA total liabilities were kr1.30B for the fiscal quarter, a 1.84% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.